NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.
NFκB
breast cancer
immunotherapy
inflammatory signaling
ovarian cancer
tumor signaling
Journal
Oncology reviews
ISSN: 1970-5565
Titre abrégé: Oncol Rev
Pays: Switzerland
ID NLM: 101519906
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
04
2022
accepted:
02
08
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Immune disorders and cancer share a common pathway involving NF-κb signaling. Through involvement with GM-CSF, NF-κB can contribute to proliferation and activation of T- and B- cells as well as immune cell migration to sites of inflammation. In breast cancer, this signaling pathway has been linked to resistance with endocrine and chemotherapies. Similarly, in ovarian cancer, NF-κB influences angiogenesis and inflammation pathways. Further, BRCA1 signaling common to both breast and ovarian cancer also has the capability to induce NF-κB activity. Immunotherapy involving NF-κB can also be implemented to combat chemoresistance. The complex signaling pathways of NF-κB can be harnessed for developing cancer therapeutics to promote immunotherapy for improving patient outcomes.
Identifiants
pubmed: 36531159
doi: 10.3389/or.2022.10568
pii: 10568
pmc: PMC9756851
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
10568Informations de copyright
Copyright © 2022 Devanaboyina, Kaur, Whiteley, Lin, Einloth, Morand, Stanbery, Hamouda and Nemunaitis.
Déclaration de conflit d'intérêts
Authors LS and JN were employed by the company Gradalis, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncogene. 2017 Feb 23;36(8):1069-1079
pubmed: 27524414
Ann Oncol. 2006 May;17(5):813-7
pubmed: 16403809
Trends Endocrinol Metab. 2005 Mar;16(2):46-52
pubmed: 15734144
Br J Pharmacol. 2011 Apr;162(7):1590-602
pubmed: 21198545
J Reprod Dev. 2004 Feb;50(1):39-46
pubmed: 15007200
Cell Res. 2011 Feb;21(2):223-44
pubmed: 21243012
Oncogene. 2006 Oct 30;25(51):6731-48
pubmed: 17072325
J Cell Physiol. 2018 Apr;233(4):3004-3015
pubmed: 28617957
Biochim Biophys Acta. 2010 Apr;1805(2):167-80
pubmed: 20079806
Pathol Oncol Res. 2019 Jan;25(1):225-231
pubmed: 29081034
J Exp Clin Cancer Res. 2013 Sep 05;32:62
pubmed: 24011086
Mol Cell Biol. 2003 Nov;23(22):8070-83
pubmed: 14585967
J Exp Clin Cancer Res. 2019 Jan 8;38(1):12
pubmed: 30621730
Oncotarget. 2017 Jan 17;8(3):3811-3825
pubmed: 28002811
Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000158
pubmed: 20300203
Oncogene. 2014 Feb 6;33(6):713-723
pubmed: 23435429
J Surg Res. 2019 Aug;240:115-123
pubmed: 30927618
Oncotarget. 2016 Nov 29;7(48):78896-78909
pubmed: 27806331
J Dermatol Sci. 2005 Nov;40(2):95-103
pubmed: 16085391
Biochem J. 2000 Jun 15;348 Pt 3:591-6
pubmed: 10839991
J Immunol. 2010 Aug 1;185(3):1606-15
pubmed: 20622119
Biochem J. 2004 Sep 1;382(Pt 2):393-409
pubmed: 15214841
Oncoimmunology. 2018 Sep 5;7(12):e1480301
pubmed: 30524886
Cancers (Basel). 2014 Apr 03;6(2):771-95
pubmed: 24704793
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
PLoS One. 2015 Apr 06;10(4):e0123410
pubmed: 25844720
J Biol Chem. 2018 Oct 5;293(40):15483-15496
pubmed: 30135206
Mol Cancer Res. 2020 Sep;18(9):1257-1270
pubmed: 32503922
J Biol Chem. 1997 Nov 14;272(46):29167-73
pubmed: 9360994
Indian J Surg Oncol. 2013 Sep;4(3):242-7
pubmed: 24426730
Mol Carcinog. 2006 Jun;45(6):355-61
pubmed: 16673382
Immunol Rev. 2012 Mar;246(1):125-40
pubmed: 22435551
J Biol Chem. 2003 Nov 14;278(46):46171-8
pubmed: 12952963
Trials. 2019 Dec 19;20(1):753
pubmed: 31856909
Mol Endocrinol. 2006 Nov;20(11):2999-3013
pubmed: 16825293
Clin Cancer Res. 2007 Sep 1;13(17):5001-9
pubmed: 17785550
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Breast Cancer Res. 2013 Feb 25;15(1):202
pubmed: 23673317
Fertil Steril. 2003 Jan;79(1):151-7
pubmed: 12524080
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Curr Cancer Drug Targets. 2018;18(8):737-748
pubmed: 28669345
Breast Cancer Res. 2012 Aug 31;14(4):212
pubmed: 22963717
Mol Endocrinol. 2004 Aug;18(8):1919-28
pubmed: 15155785
Endocr Relat Cancer. 2019 May 09;26(6):R369-R380
pubmed: 32013374
Br J Cancer. 2014 Jun 10;110(12):2965-74
pubmed: 24867687
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:235-9
pubmed: 25450861
Chin J Cancer. 2011 Sep;30(9):603-11
pubmed: 21880181
Mayo Clin Proc. 2010 Dec;85(12):1111-20
pubmed: 21123638
Am J Physiol Endocrinol Metab. 2014 Jul 15;307(2):E133-40
pubmed: 24895281
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41
pubmed: 26990581
Gynecol Oncol Rep. 2020 Sep 17;34:100648
pubmed: 33364285
J Biol Chem. 2001 Jun 1;276(22):18934-40
pubmed: 11259436
PLoS One. 2017 Jan 20;12(1):e0169622
pubmed: 28107418
Ann Thorac Surg. 2006 Jul;82(1):243-8
pubmed: 16798222
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443240
J Clin Med. 2016 Jul 14;5(7):
pubmed: 27429011
Endocr Relat Cancer. 2006 Jun;13(2):607-16
pubmed: 16728586
J Steroid Biochem Mol Biol. 1997 Jan;60(1-2):11-7
pubmed: 9182853
Cancer Res. 2018 Jan 1;78(1):205-215
pubmed: 29263152
J Biol Chem. 2000 Sep 15;275(37):28937-46
pubmed: 10874048
Oncotarget. 2016 Apr 12;7(15):19884-96
pubmed: 26943587
Oncoimmunology. 2018 Feb 1;7(5):e1423170
pubmed: 29721376
Biochem Pharmacol. 2002 Sep;64(5-6):873-81
pubmed: 12213581
Ann Med Surg (Lond). 2021 Feb 10;63:102164
pubmed: 33664949
Lancet Oncol. 2020 Jan;21(1):60-72
pubmed: 31806543
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Curr Med Chem. 2015;22(2):264-89
pubmed: 25386819
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
PLoS One. 2008 Mar 12;3(3):e1758
pubmed: 18335034
Mol Ther. 2012 Mar;20(3):679-86
pubmed: 22186789
Lancet Oncol. 2019 Mar;20(3):339-351
pubmed: 30795951
Cancer Res. 2010 May 15;70(10):4005-14
pubmed: 20424119
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Cancer Immunol Immunother. 2018 Feb;67(2):271-283
pubmed: 29090321
Gynecol Oncol. 2016 Dec;143(3):504-510
pubmed: 27678295
Oncology. 2014;87(1):21-9
pubmed: 24968881
Pharmacol Res. 2018 Apr;130:273-291
pubmed: 29305909
Cell Stem Cell. 2016 Jul 7;19(1):52-65
pubmed: 27292187
Cell Death Dis. 2018 Sep 5;9(9):908
pubmed: 30185771
Cancer Res. 2017 Dec 15;77(24):6927-6940
pubmed: 29074539
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
Breast. 2013 Oct;22(5):585-92
pubmed: 23759273
Bone. 2011 Jan;48(1):96-9
pubmed: 20950721
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Pathol Int. 2008 Dec;58(12):749-56
pubmed: 19067848
Cell Cycle. 2012 Nov 15;11(22):4152-66
pubmed: 23047606
Mol Med. 2008 Jul-Aug;14(7-8):517-27
pubmed: 18431462
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Biochem Biophys Res Commun. 2017 Mar 25;485(1):76-81
pubmed: 28188787
Pharmacogenomics. 2017 Nov;18(17):1595-1609
pubmed: 29095114
Mol Cell Biol. 1999 Jul;19(7):4798-805
pubmed: 10373529
JAMA Surg. 2017 Jun 1;152(6):589-594
pubmed: 28423155
Mol Cell Biol. 1993 Oct;13(10):6530-6
pubmed: 8105372
Cell Death Differ. 2020 Jun;27(6):1765-1781
pubmed: 31802034
Blood. 2003 Jul 1;102(1):192-9
pubmed: 12637324
Clin Transl Med. 2015 Feb 26;4:6
pubmed: 25852822
Oncogene. 2019 Jun;38(23):4452-4466
pubmed: 30755733
Mol Ther. 2015 Jun;23(6):1103-1109
pubmed: 25917459
Front Biosci (Landmark Ed). 2009 Jan 01;14(7):2514-21
pubmed: 19273216
Curr Comput Aided Drug Des. 2020;16(4):365-375
pubmed: 31749430
Hum Pathol. 2009 Jun;40(6):795-806
pubmed: 19157506
Genes Dev. 2008 Jun 1;22(11):1490-500
pubmed: 18519641
Oncogene. 2006 Oct 30;25(51):6817-30
pubmed: 17072330
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000182
pubmed: 20452952
Oncogene. 2012 Sep 13;31(37):4139-49
pubmed: 22158046
Breast Cancer Res Treat. 2008 Nov;112(1):53-62
pubmed: 18064564
Br J Cancer. 2016 Jan 12;114(1):1-6
pubmed: 26757421
Mol Ther. 2016 Aug;24(8):1478-83
pubmed: 27109631